Every material Form 8-K Atara Biotherapeutics, Inc. has filed with the SEC since June 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Atara reported a second-quarter 2026 net loss of $4.8 million, or $(0.32) per share, compared with net income of $2.4 million, or $0.20 per basic share, a year earlier. Revenue fell to $0.6 million from $17.6 million, mainly because deferred revenue was recognized in 2025 after development moved to Pierre Fabre. The company says it expects to fund operations into mid-2027, but cash stood at $9.9 million at June 30, 2026.
Commercialization revenue was $0.6 million for Q2 2026, down from $17.6 million in Q2 2025.
Net loss was $4.8 million, or $(0.32) per share, versus net income of $2.4 million in Q2 2025.
Cash, cash equivalents and short-term investments totaled $9.9 million at June 30, 2026, and are expected to fund planned operations into mid-2027.
Total costs and operating expenses fell to $5.4 million from $14.4 million a year earlier; a Type A meeting with the FDA on tabelecleucel was described as productive, with a regulatory update expected later in the quarter.
Atara Biotherapeutics said its chief accounting officer, Yanina Grant-Huerta, will leave effective July 17, 2026. The board appointed Kevin G. Sarney, a consultant from Charles River CFO, Inc., as interim chief financial officer effective June 26, 2026, and he will also serve as principal accounting officer. The change in its top finance roles is notable for shareholders because it comes through a consulting arrangement rather than a permanent hire.
Yanina Grant-Huerta, Chief Accounting Officer, was notified June 22, 2026 that her employment ends effective July 17, 2026.
Kevin G. Sarney appointed interim chief financial officer effective June 26, 2026, serving as principal financial and principal accounting officer.
Sarney's services are provided under a consulting agreement with Charles River CFO, Inc.; the Company pays an agreed hourly rate and Sarney receives no direct compensation from the Company.
The consulting agreement can be terminated by either party on 30 days written notice.
Atara Biotherapeutics appointed Brian Cherry as a Class I director effective June 11, 2026, placing him on the Audit Committee, and granted him 24,000 restricted stock units. At its June 9, 2026 annual meeting, stockholders elected two director nominees, approved an advisory say-on-pay vote, approved a 400,000-share increase to the 2024 Equity Incentive Plan, and ratified Deloitte & Touche LLP as auditor.
Brian Cherry appointed Class I director and Audit Committee member, effective June 11, 2026
Initial award of 24,000 restricted stock units vesting annually over three years; annual cash retainer of $55,000
Stockholders elected AnhCo Nguyen Ph.D. (3,543,113 for) and Nachi Subramanian (2,581,435 for) to serve until the 2029 annual meeting
Stockholders approved the equity plan amendment adding 400,000 shares and ratified Deloitte & Touche LLP for fiscal 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Atara Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →